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Abstract
Background With preliminary data suggesting an
increasing trend in attention-deficit/hyperactivity disorder
(ADHD) prevalence in Europe, the use of psychotropic
medications in this population needs to be better under-
stood, particularly among patients with ADHD and no co-
morbid psychiatric disorder.
Methods Medical charts of patients aged 6–17 years with
one or more ADHD diagnosis between January 1, 2004 and
June 30, 2007, and use of ADHD medication were
abstracted by physicians from six European countries.
Patients with a history of epilepsy or diagnosis of Tourette
syndrome were excluded.
Results Among a convenience sample of 569 children/
adolescent patients (mean age, 12.1 years), 80 (14.1 %)
patients used psychotropic concomitant medication (PCM)
along with their current on-label ADHD medication. The
number of pre-existing co-morbidities, high impairment
due to the symptom of anger, and country (France; Italy;
the Netherlands; and Spain vs. the reference country,
Germany) were significantly associated with PCM use (UK
was not significantly different vs. Germany). In particular,
in France, Italy, the Netherlands, and Spain, PCM use was
highest.
Conclusions These findings suggest that greater attention
to the use of PCM, which are not indicated for the treat-
ment of ADHD, may be warranted in children and ado-
lescents receiving PCM. This highlights the need for
further research to assess the impact of PCM use in ADHD
patients and to consider alternative, individualized, indi-
cated treatment strategies for patients with ADHD.
1 Introduction
1.1 Attention-Deficit/Hyperactivity Disorder
Treatment Options and Guidelines
In children, adolescents, and adults, attention-deficit/
hyperactivity disorder (ADHD) is a heterogeneous behav-
ioral disorder characterized by the presence of core
symptoms of inattention, hyperactivity, and impulsivity
[1]. While it is common for these core symptoms to present
together, symptoms of ADHD can also overlap with
symptoms of other related disorders and common coexis-
ting conditions, such as learning disability, oppositional
defiant disorder (ODD), conduct disorder, anxiety,
depression, bipolar disorder, Tourette syndrome, substance
abuse, or others [1, 2].
In Europe, study-reported prevalence rates of ADHD in
individual countries, in the range of 2.8–7.3 % (France
7.3 %; Germany 3.1 %; Italy 2.8 %; the Netherlands
5.0 %), have been increasing in recent years [3–5]. In the
UK, data from the British Child and Adolescent Mental
Health Survey of parents, teachers, and children indicated
that 3.6 % of boys and 0.85 % of girls between the ages of
5 and 15 years have ADHD [6]. With a large degree of
variation in clinical presentation and a high risk for co-
occurring disorders [1, 7], some European guidelines [e.g.,
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National Institute for Clinical Healthcare and Excellence
(NICE), Leitlinie der Arbeitsgemeinschaft ADHS der
Kinder- und Jugenda¨rzte eV, Guidelines of the Italian
Society of Neuropsichiatria dell’Infanzia and Adolescence
(SINPIA), the British Association for Psychopharmacol-
ogy] require a clinician with special training, such as a
child psychiatrist, to make or confirm a diagnosis of ADHD
[6]. Many studies have demonstrated the clinical efficacy
and safety of pharmacotherapy as monotherapy, which is
often prescribed for ADHD [8–11]. European guidelines
recommend that optimal management of ADHD patients
be based on a comprehensive treatment plan that includes
some form of psychosocial intervention with or without
medication [1, 12–15].
In patients with severe ADHD, pharmacologic treatment
is an option, whereas for patients who are less severe,
psychosocial interventions, such as behavioral therapy,
should be tried first [2, 6]. When pharmacologic treatment
is indicated, the European guidelines unanimously recom-
mend the use of stimulants in children, adolescents, and
adults as a first-line pharmacologic therapy [12]. Ato-
moxetine, or other nonstimulant therapies, such as cloni-
dine and guanfacine, are recognized as alternatives in most
European guidelines [2, 6, 12, 14] and are listed as first-line
pharmacologic treatment options for: (1) adults with
ADHD who began treatment in childhood; (2) when parent
or patient preference is to not use a stimulant; (3) among
patients who fail to respond or have a sub-optimal response
to stimulants; or (4) when a patient has co-morbid sub-
stance abuse, tics, or anxiety [2, 12–14, 16]. Among
school-age children, adolescents, and adults with severe
ADHD [12, 15], several European guidelines recommend
adopting a multimodal treatment plan [13, 15, 17, 18] that
may include methylphenidate, atomoxetine, or dexamfe-
tamine, depending on country-specific availability [6].
1.2 Coexisting Conditions and Concomitant Drug
Therapy
Despite published guidelines on the use of pharmacother-
apy and multimodal treatment plans for ADHD, few rec-
ommendations exist for children and adolescents who do
not respond in part or fully to recommended therapies, and
even less is known about the impact of adding on other
pharmacotherapies for treating ADHD. While seeking
treatment early for ADHD symptoms may improve
ADHD-related outcomes in children and adolescents [16,
19], the symptoms of ADHD often overlap with co-existing
developmental and psychiatric disorders [14, 20, 21], thus
increasing the importance of making optimal treatment
decisions for these ADHD patients.
Even though concomitant psychotropic medications are
not indicated according to their product label for use in
children and adolescents in the treatment of ADHD [22],
European and US studies have reported their off-label use
in this population [23]. A retrospective study of prescrip-
tion medical records data in the Netherlands reported that
antipsychotics (6 %) and melatonin (4 %) were the most
commonly used therapeutics in the year before ADHD
treatment initiation [4]. Another study conducted in the
Netherlands reported that users of ADHD medication had
used atypical antipsychotics at a rate of 5 %, while users of
lithium, valproate, and lamotrigine had tried ADHD med-
ication at a rate of 20–26 % and even used these drugs
concomitantly (15–21 %) [21]. A Danish study found that
antidepressants and antipsychotics were used at rates of
4.9 % and 7.1 %, respectively, among patients under the
age of 18 years with ADHD who also received medication
within the Anatomical Therapeutic Chemical classification
of the nervous system [24]. Further, a study among Italian
children and adolescents receiving ADHD medication
reported a 22 % rate of concomitant psychotropic medi-
cation use based on registry data from Northern Italy [25].
With two recent studies suggesting an increasing trend
in ADHD prevalence in Europe [6, 25] and little docu-
mentation of concomitant use of psychotropic drugs in this
population, the use of psychotropic medications needs to be
better understood, particularly among those patients where
their use is for ADHD—that is, patients with ADHD and
no co-morbid psychiatric disorder. As such, the purpose of
this study was to estimate the rates of psychotropic con-
comitant medication (PCM) use in six European countries
and to identify patient characteristics associated with PCM
use among children and adolescents receiving a product
label-indicated ADHD treatment.
2 Methods
2.1 Study Data and Selection Criteria
This retrospective cohort study is based on a review and
data abstraction of patient medical records by their treating
physicians in six Western European countries: the UK,
France, Germany, Italy, the Netherlands, and Spain. A
convenience sample of pediatricians, neuropediatricians,
child and/or adolescent psychiatrists, and pediatric neu-
rologists who treated patients with ADHD was identified
from physician directories maintained by local country
medical associations and physician telephone directories.
Physicians included in the database were recruited by
telephone or email and directed to an Internet-based
questionnaire to potentially participate in the study. Phy-
sicians with between 3 and 30 years of experience were
eligible for inclusion if they managed a minimum of five
patients per month with ADHD between the ages of 6 and
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17 years and were primarily responsible for making
ADHD-related treatment decisions for the patient.
Institutional Review Board study protocol review and
exemption was obtained prior to study data collection. All
data were entered by the physician via an online ques-
tionnaire translated into the language of the country. Phy-
sicians were asked to complete an ADHD patient chart
review for up to five of their most recent patients who met
the patient study age criterion, had a documented diagnosis
of ADHD between January 1, 2004 and June 30, 2007, and
had at least 2 consecutive years of follow-up post-diagnosis
(e.g., medical record information available). Patients were
also required to have received either pharmacologic treat-
ment or behavioral therapy following the ADHD diagnosis.
Eligible patient charts could have a diagnosis of ADHD
only, or ADHD combined with the presence of other
behavioral symptoms (e.g., anger, irritability), related
behavioral disorders (e.g., ODD), or psychiatric co-mor-
bidities (e.g., autism, anxiety). Symptom impairment scale
responses were evaluated in the range of 1 being the
‘‘lowest impairment’’ to 10 being the ‘‘highest impair-
ment.’’ Patient charts were excluded if there was evidence
of enrollment in a randomized clinical trial during the time
of the data abstraction. For purposes of this analysis,
additional criteria were applied to increase the likelihood
that PCM was used for ADHD. Patients with pre-existing
epilepsy or Tourette syndrome were excluded as these are
concomitant conditions that may warrant the use of psy-
chotropic medications such as neuroleptic or antiepileptic
drugs, which could have been used for both ADHD and
these concomitant conditions. In addition, patients receiv-
ing behavioral therapy alone were excluded.
2.2 Psychotropic Concomitant Medication (PCM) Use
Patients receiving both a product label-indicated ADHD
medication (with or without behavioral therapy) and any
psychotropic medication (with no product label claim for
ADHD) during current ADHD treatment—i.e., the treat-
ment the patient was receiving at the time of chart
review—were classified as PCM users. Patients receiving
product label-indicated ADHD medication (with or without
behavioral therapy) and no PCM during current ADHD
treatment were classified as ADHD medication-only
patients. ADHD medication-only patients could have used
a combination of ADHD medications that were approved
by the European Medicines Agency that also had a product
label claim for the treatment of ADHD as long as there was
no other psychotropic medication used. The psychotropic
medications included medications that may have been used
but that did not contain a product label claim for ADHD:
selective serotonin reuptake inhibitors (SSRIs), serotonin
norepinephrine reuptake inhibitors (SNRIs), tricyclic
antidepressants (TCAs), monoamine oxidase (MAO)
inhibitors, typical antipsychotics, atypical antipsychotics,
benzodiazepine/anxiolytics, a-2 agonists clonidine and
guanfacine, and antiepileptic drugs (without epilepsy
diagnosis).
2.3 Statistical Analysis of PCM Use
Pooled analyses across countries were performed to
increase sample size. Analyses were also conducted within
country, and use was described by specific type of medi-
cation class. The significance of the relationships between
baseline patient characteristics and PCM use was tested
using the Fisher’s exact test or t tests for dichotomous and
continuous variables, respectively. All statistical tests were
two-sided, and P values B0.05 were considered statistically
significant. Data were summarized using descriptive sta-
tistics for continuous variables and frequency and per-
centage for categorical variables.
2.4 Patient Characteristics Associated with PCM Use
To identify patient characteristics associated with PCM
use, analyses focused on comparisons of patients who
received PCM with their current ADHD treatment with
those who did not. A multiple logistic regression model for
current PCM use was fitted to assess the simultaneous
effect of baseline patient and treatment characteristics from
the list of covariates that tested significant in individual
bivariate tests for the outcome. This was done to limit
multi-collinearity and over-fitting of the model given that
the number of observations (e.g., sample size) may not
have been sufficiently large to allow for each individual
variable to be entered into the model. Selection of covar-
iates was performed using the stepwise variable selection
procedure with stay and remove at significance levels of
P \ 0.05. The selection results were verified using the
backwards elimination method. Interactions and second-
order terms (continuous covariates only) for covariates
testing significantly over and above the main effects were
retained. C-statistics were reported as a measure of the
model’s accuracy of prediction [26].
2.5 Sensitivity Analyses
To test the robustness of the base case rate of PCM use,
several subsets of patients were also examined. The first
analysis excluded pre-existing schizophrenia or obsessive-
compulsive disorder (OCD), in addition to the already
excluded epilepsy and Tourette syndrome patients. The
second analysis excluded patients with evidence of pre-
existing schizophrenia, OCD, epilepsy, Tourette syndrome,
autism, alcohol abuse, or substance abuse. To test the most
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extreme possibilities, all patients with any co-morbidity,
except ODD, were removed and a rate calculated. The
effect of adding all patients with behavioral therapy only
(and not on ADHD pharmacotherapy) to the base case
denominator on the rate of PCM use was also examined.
Country-specific rates of PCM use for these patients with
behavioral therapy alone were examined relative to the
original patient sample.
One last sensitivity analysis was conducted to assess the
impact of age on PCM use. Specifically, because children
(aged 6–12 years) and adolescents (aged 13–17 years) are
often quite different in clinical presentation, interaction
terms by age group were tested in the multivariate
regression models on PCM use.
3 Results
3.1 Patient Characteristics Associated with PCM Use
Of the 730 total charts of patients treated for ADHD in the
dataset, 42 patients with epilepsy (n = 3) or Tourette
syndrome (n = 39) were excluded; and of the remaining
689 charts, an additional 120 patients were excluded for
not using any ADHD medication with a product label claim
at the time of chart review (e.g., behavioral therapy only).
Therefore, a total of 569 patient charts from 283 physicians
were identified as meeting selection criteria from all six
countries. Overall, 80 (14.1 %) patients were PCM users,
and the remaining 489 only used ADHD-labeled medica-
tion(s); 22.7 % of the 569 patients were female, and the
mean age was 12.1 years. Differences in gender and age
across countries were not statistically significant (data not
shown). Atypical antipsychotics were the most commonly
used PCM (4.0 % overall, 28.8 % of PCM users); followed
by anxiolytics (3.9 % overall, 27.5 % of PCM users);
melatonin (2.1 % overall, 15.0 % of PCM users); SSRIs
(1.8 % overall, 12.5 % of PCM users); typical antipsy-
chotics (1.4 % overall, 10.0 % of PCM users); clonidine
(0.9 % overall, 6.3 % of PCM users), and SNRIs, TCAs,
MAO inhibitors, antiepileptic drugs, and a general ‘‘other’’
category (each 0.4 % overall or 2.5 % of PCM users)
(Fig. 1). Note that the percentages overall and among PCM
users are not mutually exclusive, as the same patient could
have been counted in more than one PCM category. The
rate of PCM use differed across countries (P \ 0.0001),
with the lowest rate occurring in Germany at 4.1 %
(P \ 0.0001) and the highest rate in Italy at 32.7 %
(P \ 0.0001). The high rate in Italy was primarily driven
by the high rate of anxiolytic use (23.1 %).
At baseline, PCM users had significantly higher rates of
anxiety, depression, bipolar disorder, aggression, OCD,
insomnia, ODD, and learning disability (Fig. 2). PCM
users were also significantly older (59 % aged 13–17 years
vs. 41 % aged 6–12 years, P = 0.005) and had a higher
number of pre-existing co-morbidities (mean 3.7 vs. 2.4,
P \ 0.0001) compared with the ADHD medication-only
group (Table 1). In addition, the rate of ADHD symptoms
at diagnosis differed between groups: PCM users had
higher rates of anger, irritability, and inappropriate
behavior, and also exhibited higher overall mean impair-
ment level (mean 7.2 vs. 6.3, P \ 0.0001) than the group
with ADHD medication only. PCM users also had a higher
physician-reported rate of concurrent behavioral therapy
(60 vs. 38 %, P = 0.0004) and lower levels of patient
engagement (6.0 vs. 6.6, P = 0.010). Race; education; in-
school status; employment; and ADHD among siblings,
parents, or other family members were not significantly
different between groups. Other factors that were similar
between groups included evidence of impairment at work,
school, or social settings; number of years since diagnosis;
number of treatment lines per follow-up year; and level of
family involvement in the patient’s ADHD condition and
treatment.
After controlling for baseline covariates in the multiple
logistic regression model (C-statistic = 0.76), several
variables remained significant predictors of PCM use,
Fig. 1 PCM use by country. Percentages represent proportion of
groups for which data were available. Other includes clonidine
(clonidine use: UK, 3.4 %; the Netherlands, 1.6 %; all other
countries, 0 %), SNRIs, TCAs, MAO inhibitors, antiepileptic drugs,
and a general ‘‘other’’ category. Categories were not mutually
exclusive, thus the same patient could be counted in multiple
categories. Total percentages of PCM use by country were the
following: Italy 32.7 %, France 19.0 %, the Netherlands 15.6 %,
Spain 14.2 %, UK 11.0 %, and Germany 4.1 %. PCM psychotropic
concomitant medication, SSRI selective serotonin reuptake inhibitor,
SNRI serotonin norepinephrine reuptake inhibitor, TCI tricyclic
antidepressant, MAO monoamine oxidase
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including the number of pre-existing co-morbidities [odds
ratio; OR (95 % confidence interval; CI) = 1.16 (1.01,
1.33), P = 0.03], high impairment due to symptom of
anger [OR (95 % CI) = 1.79 (1.29, 2.47) per 1 standard
deviation increase, P = 0.0005], and country [France: OR
(95 % CI) = 3.37 (1.16, 9.75), P = 0.03; Italy: OR (95 %
CI) = 5.11 (1.65, 15.79), P = 0.005; the Netherlands: OR
(95 % CI) = 3.74 (1.18, 11.78), P = 0.025; and Spain: OR
(95 % CI) = 3.73 (1.18, 11.78), P = 0.02 vs. the reference
country, Germany]. Age group was significant (overall
P = 0.035) with patients aged 13–17 years having a 1.72-
fold (95 % CI; 0.84, 3.50) higher odds of PCM use com-
pared with patients aged 6–9 years. Figure 3 shows the
estimated probability curves for PCM use by number of
pre-existing co-morbidities predicted by the multiple
logistic regression estimated equation using patient charts
in Spain as an example; first quartile (scored as 3 out of 10)
and third quartile (scored as 8 out of 10) anger impairment
scores were used as representative fixed values for all
sample-estimated probability curves and modeled in com-
bination with age group. Accordingly, a patient from Spain
aged 13–17 years with three co-morbidities and low anger
impairment (25th percentile score of 3 out of 10) would
have a 14 % estimated probability of receiving PCM ver-
sus 32 % for an identical patient with higher anger
impairment (75th percentile score of 8 out of 10).
3.2 Sensitivity Analysis Results
In the base case analysis, our sample of children and
adolescents without epilepsy or Tourette syndrome
(n = 569), a 14.1 % (95 % CI; 11.2, 17.0 %) rate of PCM
use was observed. In the first subset analysis, 541 patients
remained after patients with pre-existing schizophrenia or
OCD (n = 28) were excluded. In the second subset ana-
lysis, 512 patients remained after patients with evidence of
pre-existing schizophrenia, OCD, epilepsy, Tourette syn-
drome, autism, alcohol abuse, or substance abuse were
excluded (n = 57). The rate of PCM use among both of
these subsets was 13.3 % (95 % CIs; 10.4, 16.2 % for both
subsets).
To test the most extreme possibility, when all patients
with any co-morbidity except ODD were removed, the
PCM use rate was 7.9 % (10 patients of 126, 95 % CI; 3.2,
12.7 %). Additionally, once patients with behavioral ther-
apy only (not on ADHD pharmacotherapy; n = 120) were
added back to the original base case analysis (n = 689), the
rate of PCM use was 11.6 % (80 patients of 689, 95 % CI;
9.2, 14.0 %). Comparison of country-specific rates of PCM
use including patients with behavioral therapy only in the
denominator (relative to the overall rate of 11.6 % across
countries) was in the range of 3.4 % (Germany;
P \ 0.0001) to 15.9 % (Italy; not significant). These were
similar to rates of PCM use in the original patient subgroup
(excluding behavioral therapy).
Last, because children (aged 6–12 years) and adoles-
cents (aged 13–17 years) were observed to be quite dif-
ferent in terms of country and other baseline factors;
multivariate regression models and interaction terms by
age group were tested on PCM use and none of these terms
were statistically significant, thus indicating that the dif-
ferences in country or co-morbidity by age group were not
significant factors related to PCM use.
4 Discussion
Results from this study of six European countries indicated
that 14.1 % of children and adolescents diagnosed with and
receiving medication for ADHD with no behavioral treat-
ment were treated concomitantly with psychotropic thera-
pies, even though the psychiatric therapies were not
product label indicated for ADHD treatment across Europe.
The PCM rate of 14.1 % was observed in the sample of
children and adolescents without epilepsy or Tourette
syndrome and dropped less than a full percentage point
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Table 1 Baseline characteristics by current PCM use





Age group [n (%)] 0.0047
6–9 years 13 (16.3) 82 (16.8)
10–12 years 20 (25.0) 209 (42.7)
13–17 years 47 (58.8) 198 (40.5)
Gender [n (%)] 0.7751
Male 61 (76.3) 379 (77.5)
Female 19 (23.8) 110 (22.5)
Country [n (%)] \0.0001
France 19 (23.8) 81 (16.6)
Italy 17 (21.3) 35 (7.2)
Spain 16 (20.0) 97 (19.8)
UK 13 (16.3) 106 (21.7)
The Netherlands 10 (12.5) 54 (11.0)
Germany 5 (6.3) 116 (23.7)
Predominant symptoms/behaviors at diagnosis [n (%)]
Inattention 64 (80.0) 394 (80.6) 0.8798
Hyperactivity 58 (72.5) 339 (69.3) 0.6020
Impulsivity 59 (73.8) 326 (66.7) 0.2463
Anger 37 (46.3) 168 (34.4) 0.0447
Irritability 48 (60.0) 196 (40.1) 0.0010
Active defiance of reasonable requests 36 (45.0) 197 (40.3) 0.4626
Tendency to blame other people 20 (25.0) 89 (18.2) 0.1677
Challenges with school/work performance 60 (75.0) 363 (74.2) 1.0000
Social problems when interacting 50 (62.5) 272 (55.6) 0.2747
Difficulty making the right choices 23 (28.8) 113 (23.1) 0.3218
Inappropriate behavior 48 (60.0) 215 (44.0) 0.0107
Other 3 (3.8) 19 (3.9) 1.0000
Sleeping troubles 0 (0.0) 4 (0.8) 1.0000
Any core symptoms 77 (96.3) 476 (97.3) 0.4812
Any behavioral symptoms 78 (97.5) 463 (94.7) 0.4056
Currently on behavioral therapy [n (%)] 0.0004
Yes 48 (60.0) 188 (38.4)
No 32 (40.0) 301 (61.6)
ADHD impairment levela (scale 1–10), mean (SD)
Inattention 7.91 (1.77) 7.79 (1.70) 0.5374
Hyperactivity 7.63 (2.13) 7.13 (2.20) 0.0597
Impulsivity 7.55 (2.26) 6.79 (2.36) 0.0074
Anger 7.00 (2.44) 5.27 (2.54) \0.0001
Irritability 6.85 (2.61) 5.69 (2.42) \0.0001
Defiance 7.06 (2.20) 5.88 (2.45) \0.0001
Blame others 5.68 (2.48) 4.64 (2.43) 0.0004
School/work performance 7.86 (1.93) 7.73 (1.71) 0.5418
Social interactions 7.60 (2.10) 6.77 (2.21) 0.0017
Making right choices 6.41 (2.12) 5.45 (2.16) 0.0002
Inappropriate behavior 7.24 (2.17) 6.28 (2.23) 0.0004
Other symptoms 7.67 (2.08) 8.16 (1.95) 0.6916
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(13.3 %), when examining sensitivity analyses with subsets
of the children and adolescents who also had no reported
evidence in their medical records of other pre-existing
conditions, including schizophrenia, OCD, autism, alcohol
abuse, or drug abuse. Furthermore, among all patient
groups studied, the rate of PCM use was relatively stable
and used to treat their ADHD, as reported by their treating
physicians. By comparison, the administration rate of
psychotropic medications, specifically second-generation
antipsychotics, to children with ADHD as their only
diagnosis was reported as 14 % in a US study of Medicaid-
enrolled children [23]. Although this study did not provide
details of the use of multiple medications, patients taking
co-medications were included in the analyses. A slightly
higher rate of PCM use by patients with ADHD and no
psychiatric co-morbidities (18 %) was reported by a
nationwide physician survey conducted in the Netherlands
[27].
This study also found significant variation in PCM use
across countries. Such a result is difficult to interpret and
may relate to physician training and practice setting,
national standards and insurance systems, treatment prior-
ities, variability in other available resources such as family
and community support or supportive educational settings,
cultural norms, or differences in approved medications. For
example, Italy had the highest rate of PCM observed during
this time period and did not have any long-acting stimu-
lants approved for use, which may indicate the use of other
medications to fill a potential gap in treatment therapy.
Across all countries, important baseline differences were
noted among patients receiving PCM relative to those who
had ADHD monotherapy, suggesting differences in
demographic and clinical characteristics between segments
of the ADHD population. During the study observation
period, PCM patients had more co-morbidities, greater
occurrence of certain predominant symptoms, more use of
behavioral therapy, greater patient engagement, and greater
symptom impairment. After controlling for these baseline
differences, patients with more pre-existing psychiatric co-
morbidities or those who had a high level of impairment
due to the symptom of anger were still more likely to
receive PCM alongside their ADHD treatment.
To our knowledge, this is the first study to provide a
detailed description of children and adolescents with
ADHD receiving ADHD-indicated treatment and con-
comitant psychiatric medications across multiple Western
European countries. Other studies have examined the rate
of PCM in children and adolescents with ADHD but typ-
ically have been limited to a single region and have not
reported whether the patients had concomitant diagnosis of
psychiatric disorders [25]. The most common form of PCM
recorded in our study was antipsychotics (5.4 %). Atypical
antipsychotics have been studied as off-label treatment for
ADHD [22] but are not recognized by current practice
guidelines in Europe [2, 12, 14]. European guidelines do
not recommend the use of any psychotropic medications
for ADHD, as these therapies do not have an indication for
ADHD in children and adolescents. Rather, most European
guidelines recommend the use of stimulant therapy as first-
line pharmacologic treatment among school-age children
as part of a multimodal treatment plan, and non-stimulant
therapy in certain circumstances (e.g., when patients have a
suboptimal response or intolerable adverse effects with
stimulants [2, 13, 16]).
A majority of ADHD patients will be treated with
stimulants, which are an effective first-line treatment
Table 1 continued





Mean ADHD symptoms levela (scale 1–10), mean (SD)
ADHD core symptomsb 7.70 (1.59) 7.23 (1.54) 0.0138
Behavior symptomsc 6.96 (1.57) 5.96 (1.61) \0.0001
Other symptoms 7.67 (2.08) 8.16 (1.95) 0.6916
All symptomsd 7.16 (1.47) 6.32 (1.43) \0.0001
Other baseline characteristics
Number of pre-existing co-morbidities: mean (SD) 3.69 (2.16) 2.39 (1.94) \0.0001
Patient engageda (scale 1–10) mean (SD) 6.00 (2.28) 6.61 (1.95) 0.0114
PCM psychotropic concomitant medication, ADHD attention-deficit/hyperactivity disorder, SD standard deviation
a Scale from 1 = lowest/none to 10 = highest
b Calculated as the mean impairment for hyperactivity, inattention, and impulsivity
c Calculated as the mean impairment for anger, irritability, active defiance, tendency to blame others, challenges with school/work performance,
social problems when interacting with family/teachers and peers/colleagues, or difficulty making right choices
d Calculated as the mean impairment for all symptoms
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option of which about 70 % of patients will respond ade-
quately [28, 29]. However, approximately 30 % of patients
do not respond adequately to stimulant therapy and may
require additional interventions, either pharmacologic or
behavioral. As such, presently the use of PCM may fill
some of this void; hence the outcomes of PCM use need to
be better understood. Greater consideration should be given
to developing individual treatment strategies that allow for
different dosages and switching among different approved
medications for ADHD, in contrast to the current practice
of PCM use in ADHD with medications that do not have a
product label indication for ADHD [2]. Such strategies
would also allow the consideration of the complexities
involved in managing ADHD, relying more extensively on
clinical impression and partnerships with caretakers [30].
Consequently, further prospective studies are needed to
better understand the use patterns of PCM in ADHD and
the true impact of PCM in ADHD patients, caretakers, and
their physicians.
The main strength of this study was the geographically
wide pan-European population of children and adolescents
with ADHD that represented six European countries and
enabled a sufficient sample size to describe the rates and
demographics from this convenience sample. The use of
physician questionnaires, based on their own abstraction of
their patient’s medical record data, could have resulted in
PCM use estimates that reflect real-world treatment pat-
terns. In addition, the study design allowed for the col-
lection of data not often collected in clinical trials or
available in administrative claims databases.
This study contained certain limitations that must be
considered alongside the results. There was no process
verifying that the understanding of questions was uniform
across clinicians, and thus different interpretations of
responses for some variables may have occurred. In addi-
tion, physician responses on treatment outcome and other
covariates may appear to be related, whereas if we had
collected these data from various independent data sources,
it is possible that correlations observed in this study would
have been attenuated.
Physicians were asked if their patients received any of
the following drugs for the treatment of ADHD. Physician
responses were not confirmed by independent review of
their medical records and their response may have depen-
ded on their individual interpretation of the question, which
could result in the reporting of a PCM drug use for ADHD,
when in effect it was used for another reason. This could
possibly explain the observed correlation between baseline
co-morbidities and increased use of PCM. Prospective
studies are needed to further clarify this point. Another
limitation of this study was the possibility of selection bias
in the convenience sampling method used to select physi-
cians and study groups at baseline. For instance, PCM
proportions were different across countries, and PCM
patients seemed to be more severe at baseline and to be
diagnosed with more co-morbid illnesses. We descriptively
compared the ADHD medication only group to the PCM
users group as a normative control group. Within the
analysis of patient characteristics associated with PCM use,
we controlled for observed variables. However, neither
analysis can control for unobserved differences and there-
fore the results of the analysis should be interpreted with
care until further prospective confirmation of the study
results are obtained.
Last, although ADHD was the only confirmed diagnosis
common to all patients, it is possible that PCM may have
been prescribed for the treatment of psychiatric co-mor-
bidities (and not ADHD) for some patients. The sensitivity
analysis for the subgroup of patients who had ADHD only
reported in their medical records (with the exception of
ODD) was conducted with this concern in mind. Yet, even
in this subpopulation, there were 7.9 % of patients pre-
scribed PCM. To accurately assess the rate of patients
prescribed PCM for ADHD only, a prospective study
would have to be conducted; our data indicate that it occurs
at some frequency.
5 Conclusion
This study found that 14.1 % of children and adolescents in
six Western European nations who received PCM for
ADHD treatment received concomitant psychotropic
Fig. 3 Estimated probability of PCM use in patients from Spain by
number of pre-existing co-morbidities, age group, and anger impair-
ment level (logistic regression modeling). PCM psychotropic con-
comitant medication
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medications that were not product indicated for ADHD.
These rate results were generally robust in various sensi-
tivity analyses. Patient-level factors associated with PCM
use included the number of pre-existing co-morbidities and
high impairment due to the symptom of anger.
Greater attention should be paid to the use of PCM,
which are not indicated for the treatment of ADHD in
children and adolescents. This may be particularly needed
in France, Italy, the Netherlands, and Spain where PCM
use was highest. Additional prospective research should be
conducted to understand the implications of PCM use in
patients with ADHD and to ensure that patients with
ADHD are receiving optimal treatment and support.
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